Viewing Study NCT00042003

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:32 PM
Ignite Modification Date: 2025-12-30 @ 8:23 PM
Study NCT ID: NCT00042003
Status: COMPLETED
Last Update Posted: 2024-08-02
First Post: 2002-07-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Sponsor: Astex Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Myelogenous Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic myelogenous leukemia View
None CML View
None CML-BP View
None Blast phase View
None Decitabine View
None 5-aza-2'deoxycytidine View
None Methylation View
None STI 571 View
None Imatinib mesylate View
None Gleevec View
None BCR/ABL View